CALB2 and cancer: The median calretinin concentrations in MPM patients and in cancer-free controls were 0.79 ng/mL (IQR 0.37–1.68 ng/mL) and 0.23 ng/mL (IQR 0.16–0.33 ng/mL), respectively (Fig. 1a).